Zobrazeno 1 - 10
of 357
pro vyhledávání: ''
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Geraldine M. Jacobson, Gary Marano, Timothy D. Eubank, Malcolm D. Mattes, Patrick C. Ma, Mohammed Almubarak, Sijin Wen
Publikováno v:
Clin Lung Cancer
INTRODUCTION/BACKGROUND: This study assessed the safety and systemic (abscopal) response from the addition of local stereotactic body radiation therapy (SBRT) to checkpoint inhibitor (CPI) immunotherapy in patients with metastatic non-small cell lung
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Mandeep Banwait, Heather A. Wakelee, Maya N. White, Lecia V. Sequist, Zofia Piotrowska, Joel W. Neal, Stephen V. Liu, Kristen M. Cunanan, Daniel Hausrath, Kevin Stirling
Publikováno v:
Clin Lung Cancer
Background Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has improved survival and central nervous system (CNS) outcomes in patients with non–small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is
Autor:
Jordi Rodon, Joann Lim, Elizabeth A. Sumner, Hira Zain, Di Nguyen, Jack P. Higgins, Vivek Subbiah, Funda Meric-Bernstam, Eric T Williams, Coline Agnes Couillault, Siqing Fu, Timothy A. Yap, Kimal Rajapakshe, Aparna Hegde, Sarina Anne Piha-Paul, Shubham Pant, Michael A. Curran, Priya Bhosale, Priyamvada Jayaprakash, David S. Hong, Thomas F. Wilson, Daniel D. Karp, Ecaterina Ileana Dumbrava, Ly M. Nguyen, Cristian Coarfa
Publikováno v:
Clin Cancer Res
Purpose: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “c
Autor:
Phillip L. Palmbos, Przemyslaw Twardowski, Vivek K. Arora, Alicia K. Morgans, Dan R. Robinson, Karen E. Knudsen, Matthew S. Davenport, Maha Hussain, Neeraj Agarwal, Javed Siddiqui, Emmanuel S. Antonarakis, Jon A. Jacobson, Stephanie Daignault-Newton, Scott A. Tomlins, Wm. Kevin Kelly, Arul M. Chinnaiyan
Publikováno v:
Clin Cancer Res
Purpose: Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, blocks proliferation in a RB and cyclin D–dependent manner in preclinical prostate cancer models. We hypothesized that cotargeting androgen receptor and cell cycle with palbocicli
Autor:
Sabrina Mathey, Barbara Schmalfeldt, Eike Burandt, Volkmar Mueller, Anja Coym, Sascha Kuerti, Katharina Prieske, Anna Jaeger, Christoph Hillen, Linn Woelber
Publikováno v:
Oncology Research
Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological
Autor:
Vinay Raja, Micki Prager, Marc Hoffmann, Qamar J. Khan, Sheshadri Madhusudhana, Larry Beck, Lauren Nye, Rajvi H. Shah, Jaimie Heldstab, Dinesh Pal Mudaranthakam, Stephanie LaFaver, Roy A. Jensen, Roberto Rodríguez, Kelsey E. Larson, Gregory James Crane, Amanda L. Amin, Richard McKittrick, Venkatadri Beeki, Joshua M Staley, Lindsey Prochaska, Roberto Salgado, Maureen Sheehan, Rachel Yoder, Andrew K. Godwin, Manana Elia, Bruce F. Kimler, Larry Corum, Anuj Shrestha, Priyanka Sharma, Kathan Mehta, Christa R. Balanoff, Deepti Satelli, Jamie L. Wagner, Anne O'Dea, Milind A. Phadnis, Robert Pluenneke, Yen Y. Wang, Karissa Finke
Publikováno v:
Clin Cancer Res
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisi
Publikováno v:
Cancer Res
The sum of target lesions is routinely used to evaluate patient objective responses to treatment in the RECIST criteria, but it fails to address response heterogeneity across metastases. This study argues that spatiotemporal heterogeneity across meta
Autor:
Thamir Mahgoub, Kenneth J. O'Byrne, John Crown, Clare Hughes, Frankie A. Holmes, Virginia Espina, Anthony Davies, Marion Le Gal, Alex J Eustace, Lance A. Liotta, Kathy Gately, Norma O'Donovan, Darran P. O'Connor, Max Hasmann, Denis M. Collins, Sinead Toomey, Dalal Alsultan, Jo Ballot, Birgit Bossenmaier, N. Gaynor, Stephen F. Madden, Bryan T. Hennessy, William M. Gallagher
Publikováno v:
Clin Cancer Res
Purpose: Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine kinase inhibitors (TKIs), like lapatinib, may have added therapeutic value in com